Industry Overview

North America silent attack market was valued $2.0 billion in 2025 and is projected to reach $4.0 billion by 2035, growing at a CAGR of 7.3% from 2026 to 2035. This market includes a wide range of diagnostic, monitoring, and treatment solutions aimed at identifying and managing silent myocardial infarctions, which typically occur without obvious symptoms. Growth is primarily driven by the rising prevalence of cardiovascular diseases and increasing awareness of asymptomatic heart conditions. Technological advancements, particularly in high-sensitivity cardiac biomarker testing, AI-powered imaging systems, and wearable cardiac monitoring devices, are significantly improving early detection and patient outcomes. Furthermore, well-established healthcare infrastructure and high healthcare spending in the United States and Canada are accelerating the adoption of advanced diagnostic technologies across the region.                                                                 

Recent developments highlight strong momentum in innovation and strategic expansion. In April 2026, Medtronic completed its $585 million acquisition of CathWorks to strengthen its cardiovascular portfolio. This acquisition brings AI-powered FFRangio technology, which enhances the diagnosis of coronary artery disease and supports earlier, more accurate treatment decisions. In the same month, GE HealthCare expanded its Effortless Recon DL portfolio by introducing advanced AI-based image reconstruction technologies. These innovations improve imaging clarity and speed, enabling better detection of cardiovascular conditions, including silent heart attacks. Together, these advancements reflect the increasing integration of artificial intelligence and digital health solutions in cardiovascular diagnostics, further driving the growth of the silent heart attack market across North America.

Market Dynamics

Silent Heart Attack Detection Gets a Boost with Advanced Cardiac Biomarkers

Cardiac biomarker testing, especially troponin-based assays, continues to lead diagnostic advancements due to its exceptional sensitivity and specificity in identifying myocardial injury. The increasing use of high-sensitivity troponin tests is enabling earlier detection of silent myocardial infarctions, even among asymptomatic individuals. In 2025, Roche Diagnostics emphasized the growing clinical significance of biomarkers such as high-sensitivity troponin and NT-proBNP in enhancing early diagnosis of acute myocardial infarction (AMI) and heart failure. These biomarkers are highly effective in identifying subtle or previously undetected heart attack cases, including silent events. Their integration into clinical practice is supporting faster and more accurate decision-making for healthcare providers. This leads to timely intervention and improved patient outcomes across cardiovascular care pathways. As a result, the cardiac biomarker-driven segment is gaining stronger momentum in the North America silent heart attack market.

Smart Wearables Redefine Early Cardiac Detection

Wearable and remote monitoring devices are rapidly transforming preventive cardiac care by enabling continuous, real-time tracking of heart activity. Growing demand for home-based healthcare solutions is driving the adoption of these advanced technologies, which help detect irregularities at an early stage. In March 2026, iRhythm announced at the American College of Cardiology Annual Scientific Session ACC.26 that its Zio ambulatory ECG portfolio revealed a significant prevalence of clinically actionable arrhythmias among U.S. patients. These findings underscore the importance of long-term monitoring in identifying silent cardiac conditions that may otherwise go unnoticed. The company also introduced a new digital education platform aimed at enhancing clinician access to data and improving decision-making. Overall, these advancements highlight the growing role of wearable technology in strengthening early diagnosis and preventive cardiac care outcomes.

Market Segmentation

• Based on diagnostic, the market is segmented into electrocardiogram (ECG), cardiac biomarkers testing (Troponin, CK-MB), cardiac imaging, and wearable & remote monitoring devices.
• Based on treatment type, the market is segmented into pharmacological treatment, interventional procedures, and lifestyle & preventive management.
• Based on end user, the market is segmented into hospitals, cardiology clinics, diagnostic centers, and homecare settings.

AI Imaging Breakthrough Transforms Silent Heart Attack Interventions

Interventional procedures such as angioplasty and stent placement remain essential in treating silent heart attacks once identified, offering effective and timely cardiac care. Continuous advancements in minimally invasive techniques are significantly improving patient outcomes while shortening recovery periods. In November 2025, Siemens Healthineers introduced its AI-powered imaging chain, Optiq AI, at the Radiological Society of North America (RSNA) Conference in Chicago. This innovative solution enhances real-time image clarity and procedural precision by reducing noise and optimizing imaging parameters. It enables clinicians to perform image-guided interventions with greater accuracy and confidence. The technology also supports early detection and streamlined treatment workflows for cardiac conditions. Such advancements are driving the adoption of next-generation interventional cardiology solutions. This trend aligns with the rising demand for advanced cardiac care technologies across North America.

Regional Outlook

North America silent heart attack market is further divided by countries, including US and Canada.

US dominates the North America region in the market

US continues to lead the North America silent heart attack market, driven by a high prevalence of cardiovascular diseases and a well-established healthcare infrastructure. The country remains at the forefront in adopting advanced diagnostic technologies, including AI-enabled tools and high-sensitivity cardiac biomarker testing. Strong investments in research and development, along with continuous innovation, further reinforce its market dominance. These factors collectively enhance early detection and accurate diagnosis of silent heart attacks. In December 2025, Siemens Healthineers launched the Syngo.CT Coronary Cockpit, an AI-powered solution designed to improve coronary artery disease diagnosis through advanced CT imaging. The technology enables automated plaque analysis and enhances clinical decision-making by providing clearer visualization of coronary conditions. This advancement supports earlier and more precise detection of cardiovascular diseases, strengthening AI-driven diagnostic capabilities across North America.

Market Players Outlook

The major companies operating in the North America Silent Heart Attack market include Abbott Laboratories, Medtronic, Siemens Healthineers, Danaher, and Philips Healthcare, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In November 2025, QuidelOrtho received U.S. FDA 510(k) clearance for its VITROS high-sensitivity Troponin I (hs-cTnI) assay, expanding its cardiac diagnostics portfolio in North America. The assay enables high-sensitivity detection of cardiac troponin, allowing clinicians to identify myocardial infarction—including silent or asymptomatic cases—earlier and with greater accuracy in emergency and acute care settings. The product integrates with existing VITROS systems, supporting faster clinical decision-making and improved outcomes.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the North America silent heart attack market
• Based on the availability of data, information related to new Protections and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.